Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  5.00 0.59% 855.00 840.00 870.00 863.00 849.00 855.00 1,777 08:00:15
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 16.3 -9.7 -17.3 - 636

Maxcyte Share Discussion Threads

Showing 401 to 423 of 675 messages
Chat Pages: 27  26  25  24  23  22  21  20  19  18  17  16  Older
DateSubjectAuthorDiscuss
20/1/2021
07:26
"MaxCyte remains committed to pursuing a dual-listing on Nasdaq in 2021."
someuwin
20/1/2021
07:24
Update looks good to me. "MaxCyte licences have been granted for more than 140 cell therapy programmes, with more than 100 licensed for clinical use, and the Company has now entered into twelve clinical/commercial license partnerships with leading cell therapy and gene editing developers."
someuwin
19/1/2021
18:05
MaxCyte @MaxCyte_info ·2h Congratulations to our partner, @PrecisionBioSci, on their accepted IND application for PBCAR19B from the @FDA Precision BioSciences @PrecisionBioSci · 5h We are excited to share that the FDA accepted our IND application for PBCAR19B, our next-generation, stealth cell, CD19 allogeneic CAR T candidate for patients with R/R Non-Hodgkin Lymphoma. Read the press release here: http://bit.ly/39K7S2H #CART #CD19 #celltherapy $DTIL
someuwin
18/1/2021
21:06
news when it comes will be at 7am. Anything else would be very unusual given it’s a scheduled trading update.
nimbo1
18/1/2021
20:48
I wasn't surprised there was no update today being MLK day. I do wonder, assuming the update is positive, whether it may be released circa 12pm to give the home side a look in. Market was buying stock above mid today
assagai
18/1/2021
20:34
vOr is also owned by puretech which is also doing well. Not quite as well as McCray though!
edwardt
18/1/2021
17:34
A trading update is due this week. Public holiday in the US today but maybe whilst they were tweeting today they were busy writing the RNS for an update tomorrow?
homebrewruss
18/1/2021
15:31
MaxCyte @MaxCyte_info ·50m Our partner, Vor Biopharma, a #celltherapy #biotech targeting hematological diseases filed with the SEC to raise up to $150 million in an initial public offering: http://ow.ly/kRQs50DbmVf.
someuwin
16/1/2021
17:58
CRISPR: one of the most important inventions of the century? hTTps://www.investorschampion.com/channel/portfolio/crispr-a-hot-investment-theme-for
pob69
16/1/2021
11:47
"After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream..." http://www.pmlive.com/pharma_intelligence/After_years_of_potential,_cell_and_gene_therapy_is_ready_for_the_pharmaceutical_mainstream_1360242
someuwin
16/1/2021
10:14
From admission doc May 2020: Path to NASDAQ IPO The Directors believe that a NASDAQ listing will further enhance the Company’s reputation and underpin its position as a long-term commercial partner to its growing customer base, which is predominantly US-based. It would also provide access to a larger pool of specialist investors and the potential for broader equity research coverage. Whilst it cannot be guaranteed, the Directors are confident that a NASDAQ listing can be achieved within 18 months of Admission. The Directors appreciate the significant support they have received from UK and other investors to date during a key stage of the Company’s growth and intend to maintain the Company’s existing admission to trading on the AIM market of the London Stock Exchange for the foreseeable future alongside the intended NASDAQ listing.
davep4
15/1/2021
19:31
MaxCyte @MaxCyte_info 4m Congratulations to our partner, Vor Biopharma, on receiving IND clearance from the @FDA for VOR33, an eHSC therapy candidate being developed for the treatment of acute myeloid #leukemia (#AML): http://ow.ly/T1wX50D9RSm #stemcells #cancer #cancerresearch
someuwin
15/1/2021
18:13
Fascinating interview with MaxCyte Founder, President and CEO Doug Doerfler with BioTalk to discuss his history and the growth of the company. He also shares advice for entrepreneurs. hTTps://www.youtube.com/watch?v=iWwDU8RSeD0&ab_channel=BioHealthInnovation%2CInc
pob69
15/1/2021
15:26
Agreed - and holding RENE too. Meanwhile, looking forward to the RNS here next week.
someuwin
15/1/2021
12:45
o/t I come in peace acknowledging there will be lots of smart people on MCXT thread who might appreciate RENE story which has stealth morphed into a mRNA / CRISPR story Check out this Twitter thread... htTps://twitter.com/hareng_rouge/status/1348748130427285504?s=20
the stigologist
14/1/2021
22:30
Truly sobering article Nimbo, thank you for the link. Telephone numbers...
assagai
14/1/2021
21:36
hTTps://www.google.com/amp/s/www.barrons.com/amp/articles/with-rare-speed-gene-editing-emerges-as-biotechs-new-cutting-edge-51610655079 Barrons article estimates therapy market for crispr sickle disease is $4.8 billion p.a. Thats larger than the c.$1.6 I have read in all the analyst sell side notes. Maxcyte have a single digit royalty agreed on the sickle cell drug. Its going to be an interesting few years here.
nimbo1
14/1/2021
16:46
Two companies where shareholders on these boards dreamt of Nasdaq listings were Quindell and Burford. Better to focus on the company's ability to sell its wares than its shares.
trident5
14/1/2021
16:02
I see Crispr on a march again today. Up 150% since early november. Oh dreams of a NASDAQ listing....
assagai
14/1/2021
14:49
Maxcyte is presenting at this 3 day virtual event "Edison Open House: Global Healthcare - DISCOVER THE LEADERS & INNOVATORS OF 2021" Registration via hTTps://www.lsegissuerservices.com/spark/healthcare-companies-presenting-edison-open-house
pob69
14/1/2021
08:07
MaxCyte made a named appearance in Allogene's JPM presentation, as a technology partner. Https://ir.allogene.com/static-files/49bca875-99c4-4dc1-b037-79a9c2fd21f6 Page 22. Allogene is also committing publicly to initiation of a registrational trial for ALLO-501A in 2H21. A registrational study should attract low single digit $m milestone payments (guessing ~$3m) for MaxCyte across the duration of the study (I think there are multiple smaller triggers). The next step following this phase, if successful, would be to seek FDA approval.
gsbmba99
13/1/2021
10:13
Got them at 6.29 but only , I think because someone let a few out at mid.
assagai
13/1/2021
10:09
Postings in green ink, large emboldened red font - time to bail?
trident5
Chat Pages: 27  26  25  24  23  22  21  20  19  18  17  16  Older
ADVFN Advertorial
Your Recent History
LSE
MXCT
Maxcyte
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210421 07:32:21